Edition:
India

Amgen Inc (AMGN.OQ)

AMGN.OQ on NASDAQ Stock Exchange Global Select Market

221.82USD
1:13am IST
Change (% chg)

$1.12 (+0.51%)
Prev Close
$220.70
Open
$221.31
Day's High
$225.22
Day's Low
$219.97
Volume
524,548
Avg. Vol
1,076,676
52-wk High
$225.22
52-wk Low
$166.30

Select another date:

Fri, Nov 1 2019

Photo

Amgen takes 20.5% stake in BeiGene to sell cancer drugs in China

LOS ANGELES Amgen Inc said on Thursday it will take a 20.5% stake in BeiGene Ltd in a deal to expand the California-based biotechnology company's presence in China, the world's second largest pharmaceutical market.

UPDATE 1-Amgen takes 20.5% stake in BeiGene to sell cancer drugs in China

LOS ANGELES, Oct 31 Amgen Inc said on Thursday it will take a 20.5% stake in BeiGene Ltd in a deal to expand the California-based biotechnology company's presence in China, the world's second largest pharmaceutical market.

Amgen to take 20.5% stake in BeiGene to expand in China

LOS ANGELES, Oct 31 Amgen Inc said on Thursday it will acquire a 20.5% stake in BeiGene Ltd in a deal that will enable the California-based biotechnology company to expand its presence in China, the world's second largest pharmaceutical market.

Amgen posts higher biosimilar sales, ends neuroscience program

Amgen Inc on Tuesday said competition for its older drugs sent third-quarter revenue down 3%, but biosimilar sales were strong and the quarterly results were ahead of Wall Street estimates.

Amgen posts higher biosimilar sales, ends neuroscience program

Amgen Inc on Tuesday said competition for its older drugs sent third-quarter revenue down 3%, but biosimilar sales were strong and the quarterly results were ahead of Wall Street estimates.

UPDATE 2-Amgen posts higher biosimilar sales, ends neuroscience program

Oct 29 Amgen Inc on Tuesday said competition for its older drugs sent third-quarter revenue down 3%, but biosimilar sales were strong and the quarterly results were ahead of Wall Street estimates.

Amgen third-quarter revenue falls 3%, biosimilar sales rise

Oct 29 Amgen Inc on Tuesday said competition for older off-patent drugs sent third-quarter revenue down 3%, but share repurchases and biosimilar sales helped it achieve higher-than-expected profit, and the company raised its full-year outlook.

Amgen sets one lower list price for its cholesterol drug

Drugmaker Amgen Inc said on Thursday that starting next year, its official list price for cholesterol drug Repatha will be the lower price it began offering last year to patients on Medicare and those paying for the drug out-of-pocket.

UPDATE 1-Amgen sets one lower list price for its cholesterol drug

Oct 24 Drugmaker Amgen Inc said on Thursday that starting next year, its official list price for cholesterol drug Repatha will be the lower price it began offering last year to patients on Medicare and those paying for the drug out-of-pocket.

Amgen slashes price tag on cholesterol medicine Repatha by 60% for 2020

Oct 24 Drugmaker Amgen Inc said on Thursday starting next year it would sell its cholesterol drug Repatha exclusively at a 60% discount to its current list price.

Select another date: